On Monday, VYNE Therapeutics Inc (NASDAQ: VYNE) opened lower -4.49% from the last session, before settling in for the closing price of $0.59. Price fluctuations for VYNE have ranged from $0.28 to $4.30 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 65.87% over the past five years. Company’s average yearly earnings per share was noted 7.89% at the time writing. With a float of $31.15 million, this company’s outstanding shares have now reached $31.77 million.
VYNE Therapeutics Inc (VYNE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of VYNE Therapeutics Inc is 6.43%, while institutional ownership is 10.18%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.28 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.3) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.71% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
Check out the current performance indicators for VYNE Therapeutics Inc (VYNE). In the past quarter, the stock posted a quick ratio of 8.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.81 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
VYNE Therapeutics Inc (NASDAQ: VYNE) saw its 5-day average volume 1.92 million, a negative change from its year-to-date volume of 2.34 million. As of the previous 9 days, the stock’s Stochastic %D was 56.59%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 59.87%, which indicates a significant increase from 52.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0504 in the past 14 days, which was higher than the 0.0297 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4007, while its 200-day Moving Average is $0.8396. Nevertheless, the first resistance level for the watch stands at $0.5790 in the near term. At $0.5963, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6101. If the price goes on to break the first support level at $0.5479, it is likely to go to the next support level at $0.5341. The third support level lies at $0.5168 if the price breaches the second support level.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
There are currently 33,286K shares outstanding in the company with a market cap of 18.69 million. Presently, the company’s annual sales total 500 K according to its annual income of -39,830 K. Last quarter, the company’s sales amounted to 170 K and its income totaled -7,280 K.
